Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8250 participants.
Also called NCT04624854
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 8,250 participants
- Sponsor
- Registry
-
NCT04624854
-
- Other papers using this trial's data
- Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04624854. Randomized; no masking; primary purpose treatment. Start 2020-10-28 (actual); primary completion 2025-09-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
- Condition
- Coronary Artery Disease
- Condition
- Myocardial Ischemia
- Condition
- Acute Coronary Syndrome
- Condition
- Heart Diseases
- Condition
- Syndrome Heart Disease
- Condition
- Cardiovascular Diseases
- Condition
- Arteriosclerosis
- Condition
- Arterial Occlusive Diseases
- Condition
- Coronary Disease
- Condition
- Vascular Diseases
- Intervention (Drug)
- Clopidogrel and aspirin dual-antiplatelet therapy
- Intervention (Drug)
- Aspirin monotherapy
- Lead sponsor
- Harbin Medical University
- Collaborator
- Chinese Society of Cardiology
- Collaborator
- Lepu Medical Technology (Beijing) Co., Ltd.
Record details
- Record id
cardio:ct-nct04624854- Content hash
898f793ae4a9c56177d7f30ef1599699cf083068ab9421afd08e112ed850cf5b